Ok folks-- BOOT <-- You should all be in this name. IRDM <-- You should all be in this name. POSSIBLE GUMMY-> SGHT Stifel upgrades Sight Sciences to Buy on potential 2023 upside 07:09 SGHT Stifel analyst Thomas Stephan upgraded Sight Sciences to Buy from Hold with a price target of $15, up from $10. The analyst has a more favorable view on the stock's near-to-intermediate term setup compared to the long-term. Stephan's latest survey diligence of 41 minimally invasive glaucoma surgery-trained ophthalmologists gives him increased confidence in the company posting upside to revenue estimates in 2023. He expects a softer competitive landscape for at least the next six months for Sight Sciences. Thanks, Trip, and thank you all for joining us. Our third quarter results reflect continued strength and execution across our entire business. We are pleased with the progress we were making, penetrating and expanding both the MIGS and dry eye treatment markets, while taking the necessary steps to position the business to reach positive free cash flow in 2025. In the period, we achieved total revenue of $18.7 million, representing 43% growth year-over-year and 8% growth sequentially. Surgical Glaucoma revenue grew 37% year-over-year and 7% sequentially to $17.1 million in the third quarter, and Dry Eye revenue grew 145% year-over-year and 21% sequentially. We ended the quarter with just under $200 million of cash, which we currently expect will be more than enough to support our growth plan until we reach cash flow breakeven. Sight Sciences, Inc. (SGHT) NasdaqGS - NasdaqGS Real Time Price. 11.82-0.42(-3.43%) At close: 04:00PM EST 12.29+0.47(+3.98%)<-------------------- Pre-Market:07:07AM EST
LifeStance Health Group:LifeStance Health Group is a renowned provider of outpatient mental health care. The company announced its third-quarter 2022 results last month, wherein it registered a solid uptick in its overall revenues. It also recorded a robust improvement in its total clinicians in the reported quarter. Management is currently focusing on continuing its shift to organic growth, investing in strategic initiatives to build scalable infrastructure and driving operating leverage and profitability. Price and Consensus: LFST For this Scottsdale, AZ-based company, the Zacks Consensus Estimate for 2022 revenues suggests growth of 26.8%. The same for earnings indicates an increase of 39.1%. The company’s P/B ratio of 1.1 compares favorably with the industry’s 2.1.
LifeStance Health Group, Inc. (LFST) NasdaqGS - NasdaqGS Real Time Price. 4.4000-0.2000(-4.35%) At close: 04:00PM EST 4.7100+0.31(+7.05%)<------------ Pre-Market:07:31AM EST
Borr Drilling Limited (BORR) NYSE - NYSE Delayed Price. 4.7900+0.2100(+4.59%) At close: 04:00PM EST 4.9200+0.13(+2.71%) Pre-Market:07:24AM EST
Possible Gummy No 2- ALLO ALLO... This name again. I did not do well with this name the first time around... hesitant to use it again... I have to re check where I had this in the past.... Allogene Therapeutics, Inc. (ALLO) NasdaqGS - NasdaqGS Real Time Price. 5.81+0.01(+0.17%) At close: 04:00PM EST 6.15+0.34(+5.85%)<---------------- Pre-Market:07:38AM EST
Bluebird Bio to sell second Zynteglo PRV for $95M 07:36 BLUE Bluebird Bio announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher, or PRV, for $95M. Bluebird bio was granted two PRVs upon the FDA approvals of Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and Skysona for the treatment of early, active cerebral adrenoleukodystrophy, on August 17, 2022 and September 16, 2022 respectively. On December 29, 2022, Bluebird closed the sale of its first PRV for $102M. Bluebird received a payment of $95M upon closing of the transaction, which occurred simultaneously with the parties entering into the agreement. Jefferies acted as the exclusive financial advisor to bluebird for this transaction. Genius Sports named 2023 Top Pick, added to Conviction List at Needham 07:47 GENI, UBER Needham analyst Bernie McTernan names Genius Sports (GENI) his 2023 Top Pick and adds the stock to Needham Conviction List in place of Uber (UBER). The stock offers a reasonable valuation with significant exposure to the secular growth story of the U.S. sports betting industry, which he expects to be more resilient than other end markets in his coverage, the analyst tells investors in a research note. The company's high fixed costs should also allow Genius Sports margins to scale as revenues grow and as FX headwinds abate, McTernan adds. The analyst also notes that Uber remains his "top large-cap pick" given its emerging revenue streams from advertising and grocery, and he believes that the stock's valuation at 17.5-times expected 2023 EBITDA is "reasonable". Borr Drilling upgraded to Buy from Neutral at BTIG 07:34 BORR BTIG analyst Gregory Lewis upgraded Borr Drilling to Buy from Neutral with a $7 price target. Jackup activity is improving and, more importantly, pricing is finally inflecting higher, the analyst tells investors in a research note. The working floater count is now at its highest level since Q1 of 2020 when it averaged 126 floaters, primarily driven by increased activity in Brazil with 24 rigs working in December, up 15% from 2022 average, Lewis adds. Argus upgrades Skechers to Buy, sees the stock as undervalued 07:52 SKX Argus analyst John Staszak upgraded Skechers to Buy from Hold with a $50 price target. The company is benefiting from solid consumer spending amid higher wages and favorable direct-to-consumer trends, the analyst tells investors in a research note, also anticipating improvements at Skechers' websites and retail stores to boost its earnings. Staszak adds that Skechers looks "undervalued" at 14.4-times expected 2023 earnings vs. the five-year average multiple of 16.4-times.
Ok bottom line SKX I have been in this name for a month almost and made nothing. $1. Still lots of room to move and time for SKX.<-------- BOOT Barn we just bought yesteday<----- IRDM was our 1 stock to buy for the New Year. On top of that-- -5 To WATCH- GENI ALLO BORR LFST SGHT